NovoCure Ltd. (NVCR) PT Raised to $240 at Piper Sandler Following Early-Stage Pipeline Updates
Tweet Send to a Friend
Piper Sandler analyst Jason Bednar raised the price target on NovoCure Ltd. (NASDAQ: NVCR) to $240.00 (from $235.00) while maintaining ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
